Entrada Therapeutics (TRDA) Non-Current Assets (2020 - 2026)

Entrada Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $68.6 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 17.58% year-over-year to $68.6 million in Q1 2026; TTM through Mar 2026 was $294.0 million, a 16.28% decrease from a year earlier, with the FY2025 full-year figure at $71.1 million, down 17.57% from the prior year.
• Non-Current Assets declined to $68.6 million in Q1 2026 per TRDA's latest filing, from $71.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $103.8 million in Q2 2023 and bottomed at $39.7 million in Q3 2022.
• The 5-year median for Non-Current Assets is $79.6 million (2025), against an average of $73.9 million.
• Across the five-year window, Non-Current Assets jumped 491.35% in 2022 and declined 17.58% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $42.2 million in 2022, then jumped by 135.7% to $99.4 million in 2023, then slipped by 13.22% to $86.3 million in 2024, then retreated by 17.57% to $71.1 million in 2025, then dropped by 3.49% to $68.6 million in 2026.
• Per Business Quant, the three latest TRDA Non-Current Assets figures stand at $68.6 million (Q1 2026), $71.1 million (Q4 2025), and $74.6 million (Q3 2025).